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Abstract 
Background: Plasma membrane localization can play a significant role in the ultimate function of certain proteins. 
Specific membrane domains like lipid rafts have been shown to be inhibitory domains to a number of signaling 
proteins, including Gsα, and chronic antidepressant treatment facilitates Gs signaling by removing Gsα form lipid rafts. 
The intent of this study is to compare the effects of the selective serotnin reuptake inhibitor, escitalopram, with that of 
the mood stabilizing drug, lithium.
Results: There are a number of mechanisms of action proposed for lithium as a mood stabilizing agent, but the inter-
actions between G proteins (particularly Gs) and mood stabilizing drugs are not well explored. Of particular interest 
was the possibility that there was some effect of mood stabilizers on the association between Gsα and cholesterol-
rich membrane microdomains (lipid rafts), similar to that seen with long-term antidepressant treatment. This was 
examined by biochemical and imaging (fluorescence recovery after photobleaching: FRAP) approaches. Results 
indicate that escitalopram was effective at liberating Gsα from lipid rafts while lithium was not.
Conclusions: There are a number of drug treatments for mood disorders and yet there is no unifying hypothesis 
for a cellular or molecular basis of action. It is evident that there may in fact not be a single mechanism, but rather a 
number of different mechanisms that converge at a common point. The results of this study indicate that the mood 
stabilizing agent, lithium, and the selective serotonin reuptake inhibitor, escitalopram, act on their cellular targets 
through mutually exclusive pathways. These results also validate the hypothesis that translocation of Gsα from lipid 
rafts could serve as a biosignature for antidepressant action.
© 2015 Donati et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Despite several decades of research, no unifying hypoth-
esis for a molecular or cellular basis of action for antide-
pressant drugs or mood-stabilizing drugs has emerged. 
Several studies in both human and animal tissue suggest 
that there is lower cAMP production in depressed indi-
viduals (see reviews [1, 2]) while a recent report using 
PET imaging suggests a global decrease of cAMP in 
brains from depressed subjects [3]. The reviews above 
also suggest that effective antidepressant treatment 
increases adenylyl cyclase (AC) activity. It has also been 
observed that effective antidepressants induce movement 
of Gsα out of lipid rafts, thus increasing the association 
between Gsα and AC, elevating AC activity, and increas-
ing cAMP [4–6]. Gsα from C6 rat glioma cells migrates 
from a Triton X-100 (TX-100) resistant lipid raft contain-
ing membrane domain to a TX-100 soluble non-lipid raft 
membrane domains in response to chronic antidepressant 
treatment [4, 7] revealing Gsα as a preferential target for 
antidepressant action [4]. Taken together, these studies 
suggest that the lipid environment of the G protein may 
play an important role in its localization and function, and 
that chronic antidepressant treatment alters the mem-
brane localization of Gsα, augmenting coupling to AC [7].
Human post-mortem data reveals that depressed 
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enriched domains) compared to control subjects [8]. 
These results suggest that Gsα is less available for AC 
signaling in the depressed brain and is consistent with the 
observation that a therapeutic effect of antidepressants 
may be to move Gsα out of TX-100 resistant regions of 
the membrane and into a membrane domain where it is 
more available to interact with AC. Additionally, Gsα-
mediated AC activity is significantly lower in platelets 
from depressed subjects [9, 10]. Similar to results seen in 
cell culture these studies suggest that during depression, 
Gsα is sequestered in lipid raft-like domains and antide-
pressant treatment liberates the Gsα from these inhibi-
tory domains allowing it to more freely couple to AC. 
Furthermore, antidepressant drugs concentrate in raft-
like plasma membrane domains [11]. Thus, antidepres-
sants may exert their observed effects on cAMP signaling 
by liberating Gsα  from lipid rafts, where it accumulates 
during the course of depression [8, 12].
Lithium continues to be the primary pharmacological 
treatment for bipolar disorder. It has been shown that 
lithium and other mood stabilizers inhibit AC activ-
ity [13, 14] with lithium having a preference for Types V 
and VII AC [15]. There are numerous hypotheses on the 
mechanism of action of lithium (review by Marmol [16]) 
with one of the more current mechanisms involving inhi-
bition of GSK-3 (review by Machado-Vieira et  al. [17]). 
The involvement of serotonin and dopamine regulation 
of GSK-3 activity in the action of psychotropic drugs has 
also been recently reviewed [18–21]. Previous studies 
have shown that the effects of lithium in the treatment of 
affective disorders may be due to inhibition/decrease of 
the G-protein Giα activity and an increase in AC types I 
and II activity [22].
Currently, it is not possible to directly and noninva-
sively monitor the activity of AC or the partitioning of 
Gsα. However, if a biomarker can be identified for the 
process of making Gsα available to complex with AC, it 
would then be possible to quantify whether a given drug 
treatment is altering Gsα-AC coupling in a shorter time 
period, weeks vs months, predicting a likely therapeutic 
success. It is our current hypothesis that chronic antide-
pressant treatment, but not chronic treatment with other 
classes of drugs used to treat mood disorders, may alter 
lipid raft composition (lipids, proteins or both) so that 
the anchor for Gsα is lost and Gsα moves into non-raft 
fractions, increasing its availability to activate AC [12]. 
Escitalopram, the therapeutically active S-enantiomer of 
citalopram, liberated Gsα from detergent resistant mem-
branes of chronically treated C6 glioma cells, while R-cit-
alopram or acute drug treatment had no effect [23].
The results of the current study demonstrate that esci-
talopram facilitates the release of Gsα, but not Giα, from 
detergent resistant membrane domains while lithium and 
valproic acid do not have this effect. In fact, lithium and 
valproic acid may actually increase the movement of Gsα 
into these detergent resistant membrane domains.
Results
Effect of antidepressant vs lithium on Gsα TX‑100 resistant 
membrane localization
Chronic antidepressant treatment has been shown to 
decrease the localization of Gsα in detergent resistant 
membrane domains (lipid rafts), both in cerebral cortex 
membranes from rats and in C6 glioma cells [4, 7, 23]. 
Despite its structural similarity to tricyclic antidepres-
sants, chlorpromazine did not have this effect [7, 25]. To 
test whether two of the more common mood stabilizing 
drugs, lithium and valproic acid, had similar effects as 
antidepressants, C6 cells were exposed to escitalopram, 
lithium, or valproic acid. Extraction of the membranes 
with TX-100 followed by sucrose density gradient cen-
trifugation allows for the purification of signaling mol-
ecules within detergent resistant membranes [24]. The 
results show that while escitalopram reduced the amount 
of Gsα in the lipid raft compared with drug-free control 
cells, lithium and valproic acid had the opposite effect 
(Figure 1). There is translocation of Gsα out of lipid raft 
domains caused by the antidepressant escitalopram and 
a shift of Gsα into the lipid raft domains by the mood 
stabilizing agents, lithium and valproic acid compared 
to control. Additionally, there is a significant difference 
compared to escitalopram treatment (p < 0.005 for valp-
roic acid and lithium).This experiment demonstrated that 
an antidepressant stimulated the movement of Gsα out of 
lipid rafts, while the two mood stabilizers had the oppo-
site effect.
Effect of antidepressant vs lithium on Giα TX‑100 resistant 
membrane localization
Previous studies have shown that, while a number of dif-
ferent antidepressants alter the association of Gsα with 
lipid rafts, the localization of Giα remains unaffected [4, 
7, 25]. This suggested that the antidepressants were not 
altering lipid rafts, but were altering the anchoring of 
Gsα to those rafts. Figure  2 demonstrates that neither 
escitalopram nor lithium alters the membrane localiza-
tion of Giα in C6 glioma cells (Figure 2). While valproic 
acid appears to increase the amount of Giα in the lipid 
rafts, there is a much greater variability between trials 
compared to escitalopram and lithium treatment. Con-
gruent with this result and the results of the study men-
tioned above, it appears that enhancing Gsα mobility out 
of lipid raft domains may in fact, be a hallmark of antide-
pressant action.
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Effect of antidepressant vs lithium on Gsα and Giα 
membrane mobility
Lateral mobility within the plasma membrane of Gsα as 
determined by fluorescence recovery after photobleach-
ing (FRAP), changed following 1–3  days (depending on 
concentration) of antidepressant treatment [12]. Specifi-
cally, the half-time to recovery of GFP-Gsα is increased, 
likely due the increased association of Gsα, with the 
slow-moving adenylyl cyclase. In contrast, FRAP of GFP-
Giα1 was unchanged after antidepressant treatment. A 
typical membrane bleaching and recovery of fluorescence 
is shown in Figure 3a. Escitalopram treated cells demon-
strate a shorter total recovery (increased “immobile frac-
tion”), perhaps because Gsα is bound to adenylyl cyclase 
(Figure 3b). Additionally, escitalopram treated cells have 
a less steep recovery curve than either control or lithium 
treated cells, which have similarly shaped curves. That is, 
they recover their fluorescence more slowly (increased 
half time of recovery). Figure  4 shows GFP-Gsα FRAP 
after 3 days of treatment with lithium chloride (3 mM), 
valproic acid (300 μM), escitalopram (10 μM), or escit-
alopram plus lithium combined (same doses as individual 
treatments with these compounds). While lithium and 
valproic acid treatment show no effect on Gsα mem-
brane mobility compared to vehicle, treatment with 
escitalopram or escitalopram plus lithium shows the 
characteristic slowing of Gsα mobility as demonstrated 
by an increase in recovery half-time compared to vehi-
cle (p < 0.0005 for escitalopram and p < 0.0005 for esci-
talopram plus lithium). In contrast, FRAP of GFP-Giα1 is 
Figure 1 Gsα is removed from lipid rafts subsequent to antidepressant treatment while lithium has the opposite effect. Cells were treated as 
indicated in “Methods” and lipid rafts were isolated using sucrose gradient flotation. The amount of Gsα was determined by Western blot. a The 
figure shows the percentage of change in Gsα protein compared to control in the lipid raft membrane fractions (n = 7 for control, escitalopram 
and lithium; n = 5 for valproic acid). Data were analyzed by one-way ANOVA (p < 0.0006) followed by Tukey’s multiple comparison test for post hoc 
comparison of means. Data are represented as mean ± SEM (**, p < 0.005 compared to escitalopram). b A representative immunoblot of lipid raft 
Gsα from the various treatment paradigms as explained in “Methods”. C control, E escitalopram, L lithium, V valproic acid.
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unaltered by the aforementioned treatments (Figure  5), 
suggesting again that the effects of these drugs are not 
mediated through actions on Giα1.
Discussion
While primary targets of many antidepressant drugs may 
be proteins mediating monoamine uptake or catabo-
lism, there may also be postsynaptic actions, including 
increased cAMP production and a cascade of events 
resulting from sustained increase in cAMP or the activa-
tion of Gsα [1]. Recent results suggest that Gsα/adenylyl 
cyclase coupling may be one of the targets of antidepres-
sant action, and that chronic treatment is required to 
observe this effect via altered membrane localization [10]. 
Previous studies demonstrated that chronic antidepres-
sant treatment-induced increases in Gsα movement from 
a TX-100 insoluble lipid raft rich domain to a TX-100 
soluble membrane domain with a concurrent increase in 
coupling to adenylyl cyclase [7]. These results are consist-
ent with a study revealing that a number of antidepres-
sant drugs concentrate in detergent insoluble membrane 
domains, like lipid rafts, subsequent to chronic treatment 
[11]. Preclinical, platelet, and postmortem brain data 
indicate that, in depression, the G-protein Gsα is more 
likely to reside in detergent insoluble lipid rafts [5, 8, 9]. 
There is evidence that other proteins potentially involved 
in a mechanism of depression also show altered lipid raft 
localization. SERT clustering in lymphocyte lipid rafts is 
altered in a rat model of depression, relative to controls. 
[26].
The model system used in these studies, C6 glioma 
cells, has been used for antidepressant studies by this 
Figure 2 Giα membrane compartmentalization is not altered by chronic antidepressant or lithium treatment. Purified lipid rafts isolated using 
sucrose gradient flotation revealed that neither chronic antidepressant treatment nor chronic lithium treatment move Giα out of lipid rafts. a The 
figure shows the percentage of change in Giα protein in the lipid raft membrane fractions compared to control (n = 4 for control, escitalopram, 
and lithium; n = 3 for valproate). Data were analyzed by one-way ANOVA followed by Tukey’s multiple comparison test for post hoc comparison of 
means. Data are represented as mean ± SEM b A representative immunoblot of lipid raft Gsα from the various treatment paradigms as explained in 
“Methods”. C control, E escitalopram, L lithium, V valproic acid.
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and other labs [4, 7, 11, 12, 23, 25, 37]. Direct compari-
sons have demonstrated similar effects of prolonged 
drug treatment as seen in rats, except that 3 weeks in rats 
were identical to 3 days in cell culture [7]. While the pre-
sumption is that neurons are the dominant factor in both 
depression and antidepressant response, a role for glia 
(alone or in combination with neurons) is both likely and 
unresolved.
Chronic antidepressant treatment (in rats and cultured 
cells) moves Gsα out of TX-100 insoluble lipid raft rich 
domains and into a domain more amenable to an associa-
tion with adenylyl cyclase [1, 4], this action may explain 
the sustained increases in cAMP signaling that accom-
pany antidepressant treatment [2]. A previous study 
also provided evidence that Gsα signaling was inhibited 
in TX-100 insoluble lipid raft rich domains [24]. These 
data are consistent with the hypothesis that liberation of 
Gsα from these detergent insoluble inhibitory membrane 
domains by chronic treatment with antidepressants leads 
to increased coupling between signaling molecules in the 
detergent soluble non-raft membrane regions.
Lithium has been used as a treatment for bipolar dis-
order for over 50 years and has been effective in treating 
both acute manic and depressive symptoms, in addi-
tion to reducing their occurrence [27, 28]. A number of 
studies have demonstrated that lithium inhibits adenylyl 
cyclase activity [29–32] and more specifically type V ade-
nylyl cyclase [13]. Additionally, one potential mechanism 
of the antidepressant action of lithium is via inhibition of 
GSK-3 [14, 33–35]. Recent evidence suggests that lithium 
has a membrane delimited dual function in inhibiting 
the activation of G-protein activated K+ channels [36]. 
This was suggested to be due to decreased affinity of the 
Gα subunit for the Gβγ subunit and diminished GDP-
GTP exchange on the Gα subunit. What is unknown is 
whether chronic lithium treatment has any effect on the 
TX-100 insoluble lipid raft membrane localization of 
Gsα. In this vein, we set out to test whether lithium has 
the ability to alter Gsα localization in TX-100 insoluble 
lipid raft rich domains in an antidepressant manner. In 
addition, we used a structurally disparate mood stabilizer, 
valproic acid, to see if the effects were similar to lithium. 
In light of mood stabilizers’ effect on Gsα membrane dis-
position as determined by membrane fractionation and 
immunoblotting (Figure  1), these data are not sufficient 
to suggest that Gsα movement into lipid raft fractions 
Figure 3 FRAP suggests increased release of GFP-Gsα from lipid rafts after chronic antidepressant but not lithium treatment. a Typical course of 
photobleaching with representative images of cell before photobleaching (t = −3 s), immediately after photobleaching (t = 0 s), and after maximal 
recovery of fluorescence (t = 45 s). b Demonstration of typical fluorescence recovery after photobleaching in cells treated with escitalopram 10 µM 
or LiCl 3 mM for 72 h as described in “Methods”. Yellow arrows indicate area of bleach and recovery.
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and the decreased cellular production of cAMP associ-
ated with lithium or valproic acid treatment [13] are due 
to a decreased association of Gsα with adenylyl cyclase. 
Rather, it likely reflects a G protein-independent pathway 
of adenylyl cyclase regulation.
Curiously, while the above membrane fractionation 
data demonstrates movement of Gsα into lipid rafts 
upon treatment with lithium (Figure  1), we did not 
observe changes in membrane localization of Giα (Fig-
ure 2), nor FRAP recovery half-time of either GFP-Gsα 
or GFP-Giα (Figures 3, 4, 5). One interpretation of this 
is that the physical coupling between GFP-Gsα or GFP-
Giα and adenylyl cyclase is not altered by lithium treat-
ment, and that regulation of cellular cAMP levels by 
lithium is not effected by direct G protein regulation of 
adenylyl cyclase. The lack of effect by lithium on escit-
alopram-mediated Gsα FRAP (Figure  4) further sug-
gests a different locus of action. These effects on Gsα raft 
domain localization may partially explain why lithium 
is not effective as a stand alone treatment for chronic 
depression.
The decreased mobility of GFP-Gsα subsequent to anti-
depressant treatment was initially surprising to us, as we 
had hypothesized the “liberation” of Gsα from lipid raft 
domains would produce the opposite effect, increased 
mobility of GFP-Gsα and faster recovery of fluorescence 
after photobleaching (i.e., decreased half-time to recov-
ery). Instead, we found, consistently, that the movement 
of Gsα out of lipid rafts upon antidepressant treatment 
was associated with a slowing of GFP-Gsα mobility and 
an increase in half-time to recovery. We have proposed 
that this phenomenon is due to the increased asso-
ciation of Gsα, a smaller, peripheral membrane protein, 
with the larger, multi-transmembrane spanning adeny-
lyl cyclase, which displays extremely slow lateral mobil-
ity and has been shown to increase physical association 
with Gsα subsequent to antidepressant treatment [37]. 
This “molecular signature” is typical of the many antide-
pressants tested by our lab (all major groups and several 
atypical compounds) [4, 7, 12, 23]. Other psychotropic 
molecules (e.g. antipsychotics and anxiolytics) did not 
alter mobility of Gsα [12].
Figure 4 FRAP suggests that lithium combined with antidepressant does not reverse the effect of antidepressant GFP-Gsα was stably expressed 
in a C6 glioma cell line. Half-time to recovery of GFP-Gsα is increased after chronic escitalopram treatment, suggesting increased coupling with 
its effector, adenylyl cyclase. Lithium combined with escitalopram does not affect this value, suggesting an alternate locus of action for lithium. 
GFP-Gsα recovery is not altered by lithium or valproic acid treatment, suggesting unaltered coupling of GFP-Gsα with adenylyl cyclase. Sample size 
represents the number of cells assayed, with a minimum of 21 and a maximum of 101 cells assayed per experiment. Data were analyzed by one-
way ANOVA (p < 0.0001) followed by Tukey multiple comparison test for post hoc comparisons of means. Data are represented as mean ± SEM (***, 
p < 0.0005 compared to vehicle).
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Conclusions
Taken together, these observations demonstrate that the 
increased liberation of Gsα from the TX-100 insoluble 
lipid raft membrane domains is unique to antidepres-
sant drugs. Additionally, this result appears to be Gsα 
specific as Giα does not have the same response. Previ-
ous studies have demonstrated this outcome as well [7, 8, 
25]. These findings are supported by evidence suggesting 
that antidepressant drugs concentrate in raft-like plasma 
membrane domains [11], which may physically inhibit 
the localization of Gsα. Thus, it appears that one effect of 
antidepressants may be to exert their observed effects on 
cAMP signaling by liberating Gsα from TTX-100 resist-
ant membrane domains, where it accumulates during the 
course of depression. Mood stabilizing drugs like lithium 
and valproate do not affect lipid raft membrane domains 
and do not increase association of Gsα with adenylyl 
cyclase. The alteration in the membrane localization of 
Gsα may one day prove to be one of a number of useful 
biomarkers for human depression and response to anti-
depressant therapy.
Methods
Cell culture and drug treatment
C6 cells in 150 cm2 flasks were cultured in Dulbecco’s mod-
ified Eagle’s medium, 4.5 g of glucose/l, 10% newborn calf 
serum (Hyclone Laboratories, Logan, UT, USA), 100 mg/
ml penicillin and streptomycin at 37°C in humidified 5% 
CO2 atmosphere. The cells were treated with 10 µM esci-
talopram (gift from Lundbeck, Copenhagen, Denmark), 
3  mM Lithium chloride (Sigma-Aldrich, St. Louis, MO, 
USA), 300  µM sodium valproic acid (Sigma-Aldrich, St. 
Louis, MO, USA), dissolved in water. Cells were treated for 
3 days as 3 day treatment in culture has given results simi-
lar to chronic in vivo treatment for 3 weeks in rats [7]. The 
culture media and drug were changed daily. There was no 
apparent change in morphology of cells during the period 
of exposure to antidepressants.
Cell membrane, lipid raft, and detergent extract 
preparation
After treatment, cells were washed and harvested in 
ice-cold Phosphate-Buffered Saline (Mediatech Inc.). 
Figure 5 GFP-Giα FRAP is unaffected by chronic antidepressant or mood stabilizer treatment. Giα-GFP was stably expressed in a C6 glioma cell 
line. Half-time to recovery of Giα-GFP is not altered by chronic treatment with escitalopram, lithium, or valproic acid. This suggests that the change 
in membrane compartmentalization of Gsα is not due to direct effects of these agents on lipid rafts, but that the effects of antidepressants are 
specific to Gsα. Sample size represents the number of cells assayed, with a minimum of 26 and a maximum of 46 cells assayed per experiment. 
Data were analyzed by one-way ANOVA followed by Tukey multiple comparison test for post hoc comparisons of means. Data are represented as 
mean ± SEM.
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TX-100 insoluble membrane fractions were prepared as 
described by Li et  al. [24], with slight modification [4]. 
In brief, two flasks of C6 cells were scraped into 0.75 ml 
of HEPES buffer (10  mM HEPES, pH 7.5, 150  mM 
NaCl, 1  mM DTT, and protease inhibitors) containing 
1% TX-100. Cells were homogenized with 10 strokes of 
a Potter–Elvehjem homogenizer. The homogenate was 
then mixed with an equal volume of 80% sucrose pre-
pared in HEPES buffer to form 40% sucrose and loaded 
at the bottom of an ultracentrifuge tube. A step gradi-
ent was generated by sequentially layering 30, 15, and 
5% sucrose over the homogenate. Gradients were centri-
fuged at 2,00,000g for 20 h in an SW55 rotor (Beckman, 
Palo Alto, CA, USA). Two or three opaque bands were 
confined between the 15 and 30% sucrose layers. These 
bands were removed from the tube, diluted threefold 
with HEPES buffer, and pelleted in a microcentrifuge at 
16,000g. The pellet was resuspended in HEPES buffer and 
subsequently analyzed by immunoblotting.
SDS‑PAGE and western blotting
Samples were assayed for protein via a bicinchoninic 
acid assay (Pierce Research, Rockford, IL, USA) and 
equal quantities were loaded onto Stain-Free acrylamide 
gel for SDS-PAGE (Bio-Rad, Hercules, CA, USA). Gels 
were transferred to Immobilon-P PVDF membranes 
(EMD Millipore, Billerica, MA, USA) for western blot-
ting. The membranes were blocked with 5% nonfat dry 
milk diluted in TBS-T (10 mM Tris–HCl, 159 mM NaCl, 
and 0.1% Tween 20, pH 7.4) for 1 h. Following the block-
ing step, membranes were washed with Tris-buffered 
saline/Tween 20 and then incubated with an anti-Gsα 
monoclonal antibody (NeuroMab clone N192/12, Davis, 
CA, USA, catalog # 75-211, RRID #AB_2315846), anti-
Gsα polyclonal antibody (EMD Millipore, Billerica, MA, 
USA, catalog # 06-237, RRID # AB_310078), or anti-Giα 
polyclonal antibody (Thermo Scientific, Rockford IL, 
USA, catalog # PA1-1000, RRID # AB_2232440) over-
night at 4°C. Membranes were washed with TBS-T and 
incubated with a secondary antibody [HRP-linked anti-
mouse antibody IgG F(ab′)2 or HRP-linked anti-rabbit 
antibody IgG F(ab′)2] (Jackson ImmunoResearch, West 
Grove, PA, USA, catalog # 115-036-072 for mouse, 
RRID # AB_2338525 and catalog # 111-036-047 for 
rabbit, RRID #AB_2337945) for 1  h at room tempera-
ture, washed, and developed using ECL Luminata Forte 
chemiluminescent reagent (Millipore, Billerica, MA, 
USA). Blots were imaged using Chemidoc computerized 
densitometer (Bio-Rad, Hercules, CA, USA) and quanti-
fied by ImageLab 3.0 software (Bio-Rad, Hercules, CA, 
USA). In all experiments, the original gels are visualized 
using BioRad’s Stainfree technology to verify protein 
loading.
Fluorescence recovery after photobleaching (FRAP)
C6 glioma cells were transfected with either GFP-Gsα 
or GFP-Giα1  and cells stably expressing the fluorescent 
construct were selected with G418 followed by fluores-
cence activated cell sorting and isolation of clones [12]. 
Cells were plated on glass microscopy dishes and treated 
with lithium chloride (3  mM), valproic acid (300  μM), 
escitalopram (10 μM), or escitalopram plus lithium com-
bined (same doses as individual treatments with these 
compounds) for 3  days. On the day of imaging, drug 
was washed out for 1 h prior to imaging and media was 
replaced with low serum (2.5% NCS) phenol red-free 
DMEM to reduce background fluorescence. Tempera-
ture was maintained at 37°C using a heated stage assem-
bly during imaging, which utilized a Zeiss LSM 710 at 
512 × 512 resolution using an open pinhole to maximize 
signal but minimizing photobleaching. 150 data points 
approximately 300  ms apart, including 10 pre-bleach 
values, were measured for each cell. Zeiss Zen software 
was used to calculate FRAP recovery half-time utiliz-
ing a one-phase association fit, correcting for total pho-
tobleaching of the analyzed regions.
Statistical analysis
All of the experiments were performed at least three 
times. Data were analyzed for statistical significance 
using a one-way ANOVA followed by Tukey test for post 
hoc multiple comparisons of means. Values of p  <  0.05 
were taken to indicate significance.
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